Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 693

Sort by

Sort Order Select

Journal Articles

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Blood (2025) 146 (19): 2350–2356.

https://doi.org/10.1182/blood.2025028985

Published: 2025

Includes: Supplemental data

Journal Articles

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Blood blood.2024027948.

https://doi.org/10.1182/blood.2024027948

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2 -mutated post-MPN AML

Blood (2025) 146 (3): 341–355.

https://doi.org/10.1182/blood.2024027117

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Blood (2025) 145 (17): 1870–1875.

https://doi.org/10.1182/blood.2024026700

Published: 2025

Includes: Supplemental data

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Blood (2024) 144 (Supplement 1): 7367.

https://doi.org/10.1182/blood-2024-207521

Published: 2024

Journal Articles

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Blood (2024) 144 (Supplement 1): 6418.

https://doi.org/10.1182/blood-2024-210619

Published: 2024

Journal Articles

Metronomic Low-Dose Regimen of Decitabine and Venetoclax Is Safe and Efficacious for Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 6723.

https://doi.org/10.1182/blood-2024-211307

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Blood (2024) 144 (Supplement 1): 57.

https://doi.org/10.1182/blood-2024-211685

Published: 2024

Journal Articles

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

Blood (2024) 144 (Supplement 1): 6175.

https://doi.org/10.1182/blood-2024-208911

Published: 2024

Journal Articles

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

M Bakri Hammami, Jeevan Shivakumar, Nina Samuel, Rajvi Gor, Mendel Goldfinger, Noah Kornblum, Lauren Shapiro, Aditi Shastri, Ridhi Gupta, David Levitz, Marina Konopleva, Eric J. Feldman, Kira Gritsman, R. Alejandro Sica, Ioannis Mantzaris, Amit Verma, Dennis L Cooper, Nishi Shah

Blood (2024) 144 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2024-208770

Published: 2024

Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Blood (2024) 144 (Supplement 1): 4265.2.

https://doi.org/10.1182/blood-2024-201582

Published: 2024

Journal Articles

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Blood (2024) 144 (Supplement 1): 4265.5.

https://doi.org/10.1182/blood-2024-208998

Published: 2024

Journal Articles

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Blood (2024) 144 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2024-211956

Published: 2024

Journal Articles

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Carolin S. Escherich, Zhenhua Li, Kelly R. Barnett, Yizhen Li, Megan Walker, Wenjian Yang, Xin Huang, Jiyang Yu, Wendy Stock, Elisabeth Paietta, Marina Konopleva, Steven M. Kornblau, Mark R. Litzow, Hiroto Inaba, Ching-Hon Pui, Mignon L. Loh, Daniel Savic, Jun J. Yang

Blood (2024) 144 (Supplement 1): 830.

https://doi.org/10.1182/blood-2024-198800

Published: 2024

Journal Articles

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Zhe WANG, Xufeng Chen, Simone Sidoli, Anna Skwarska, Yannan Jia, Lei Yang, Varun Gupta, Shikhar Sharma, Iannis Aifantis, Hussein A. Abbas, Naval Daver, Qi Zhang Tatarata, Marina Konopleva

Blood (2024) 144 (Supplement 1): 207.

https://doi.org/10.1182/blood-2024-198057

Published: 2024

Journal Articles

Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3 -Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor

Nicholas J. Short, Sanam Loghavi, Musa Yilmaz, Omer Karrar, Joseph E. Jabbour, Courtney D. DiNardo, Tapan M. Kadia, Gautam Borthakur, Ghayas C. Issa, Hussein A. Abbas, Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian, Naval Daver

Blood (2024) 144 (Supplement 1): 220.

https://doi.org/10.1182/blood-2024-210891

Published: 2024

Journal Articles

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1 -Mutated Myeloid Malignancies

Blood (2024) 144 (Supplement 1): 642.

https://doi.org/10.1182/blood-2024-201970

Published: 2024

Journal Articles

KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

Leah Kravets, Mirca S. Saurty-Seerunghen, Divij Verma, Ariel Fromowitz, Srabani Sahu, Bradley Rockwell, Olivia Sakaguchi, Swathi Narayanagari, Shanisha Gordon Mitchell, Milagros Carbajal, Srinivas Aluri, Jingli Wang, Lindsay Lafave, Marina Konopleva, Anna S. Nam, Amit Verma

Blood (2024) 144 (Supplement 1): 326.

https://doi.org/10.1182/blood-2024-208924

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2 -mutated post-MPN AML

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Metronomic Low-Dose Regimen of Decitabine and Venetoclax Is Safe and Efficacious for Chronic Myelomonocytic Leukemia

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

Current Trends of Severe Renal Impairment in Newly Diagnosed Multiple Myeloma: A Single-Center Experience in a Low Socio-Economic Population

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3 -Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1 -Mutated Myeloid Malignancies

KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only